SCHEMBL5255667

SCHEMBL5255667

COc1ccc(S(=O)(=O)NCC2CCCN(Cc3ccc(-c4nc5ccccc5nc4-c4ccccc4)cc3)C2)cc1OC

nearest known ligand 0.56

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 4/20 0.56
▸ KMT2A Q03164 4/20 0.56
▸ POLB P06746 5/20 0.55
▸ NPC1 O15118 1/20 0.50
▸ ADRA1A P35348 1/20 0.49
▸ ADRA1B P35368 1/20 0.49
▸ BCHE P06276 1/20 0.46
▸ ALDH1A1 P00352 4/20 0.45
▸ GAA P10253 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ PKM P14618 1/20 0.43
▸ CYP2D6 P10635 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5257682 0.87 POLB (0.61) MEN1KMT2APOLBNPC1BCHE
SCHEMBL5259556 0.85 MEN1 (0.56) MEN1KMT2APOLBNPC1BCHE
SCHEMBL5261688 0.84 POLB (0.51) MEN1KMT2APOLBNPC1BCHE
SCHEMBL5261825 0.80 POLB (0.64) MEN1KMT2APOLBBCHEALDH1A1
SCHEMBL5256458 0.79 POLB (0.55) MEN1KMT2APOLBALDH1A1GAA
SCHEMBL14532091 0.78 ALDH1A1 (0.59) MEN1KMT2APOLBNPC1ADRA1A
SCHEMBL5256254 0.77 POLB (0.57) MEN1KMT2APOLBBCHEALDH1A1
SCHEMBL18105310 0.75 BCHE (0.73) MEN1KMT2APOLBNPC1BCHE
SCHEMBL5258383 0.73 MEN1 (0.51) MEN1KMT2APOLBBCHEL3MBTL1
SCHEMBL5333346 0.72 HTT (0.56) MEN1KMT2APOLBNPC1BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1496896-A4 INHIBITORS OF AKT ACTIVITY MERCK & CO INC (US) 2007-10-31 — — EP claimed
US-7223738-B2 Inhibitors of Akt activity MERCK & CO., INC. (US) 2007-05-29 — — US claimed
US-20050222155-A1 Inhibitors of akt activity MERCK SHARP & DOHME CORP. 2005-10-06 — — US claimed
EP-1496896-A1 INHIBITORS OF AKT ACTIVITY Merck & Co., Inc. (US) 2005-01-19 — — EP claimed
WO-2003086394-A1 INHIBITORS OF AKT ACTIVITY MERCK & CO., INC. (US) 2003-10-23 — — WO claimed
EP-1496896-A4 INHIBITORS OF AKT ACTIVITY MERCK & CO INC (US) 2007-10-31 — — EP disclosed
US-7223738-B2 Inhibitors of Akt activity MERCK & CO., INC. (US) 2007-05-29 — — US disclosed
US-20050222155-A1 Inhibitors of akt activity MERCK SHARP & DOHME CORP. 2005-10-06 — — US disclosed
EP-1496896-A1 INHIBITORS OF AKT ACTIVITY Merck & Co., Inc. (US) 2005-01-19 — — EP disclosed
WO-2003086394-A1 INHIBITORS OF AKT ACTIVITY MERCK & CO., INC. (US) 2003-10-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222155-A1 Inhibitors of akt activity AKT1, AKT2, AKT3 MEN1 2983/4885KMT2A 1352/4885POLB 2450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback